European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 - Baccarani, Michele; Deininger, Michael W.; Rosti, Gianantonio; Hochhaus, Andreas; Soverini, Simona; Apperley, Jane F.; Cervantes, Francisco; Clark, Richard E.; Cortes, Jorge E.; Guilhot, François; Hjorth-Hansen, Henrik; Hughes, Timothy P.; et al. (Blood, 2013)
Keywords: Antineoplastic Agents - therapeutic use; Benzamides - therapeutic use; Dasatinib; Europe; Fusion Proteins, bcr-abl - metabolism; Human health and pathology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy; Life Sciences; Piperazines - therapeutic use; Prognosis; Pyrimidines - therapeutic use; Randomized Controlled Trials as Topic; Review; Stem Cell Transplantation; Thiazoles - therapeutic use; Treatment Outcome; Europe; leukemia; dasatinib; nilotinib; myelocytic; second line treatment; imatinib mesylate; withdrawing treatment; cytogenetics; chronic; protein-tyrosine kinase inhibitor; polymerase chain reaction; allogeneic stem cell transplant